porcine dynorphin a(1 13)

Porcine dynorphin A(1-13) acetate (Dynorphin A Porcine Fragment 1-13 acetate) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations. Exposure to dynorphin A (1-13) causes acute increases in [Ca2+]i in individual neurons similar to increases seen with acute NMDA treatment.

[DAla2] Dynorphin A (1-13), amide (porcine) is a peptide that potentially acts as a κ opioid receptor agonist. It is used in the research of the nervous system [1].

Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations. Exposure to dynorphin A (1-13) causes acute increases in [Ca2+]i in individual neurons similar to increases seen with acut

[DAla2, DArg6] Dynorphin A, (1-13) (porcine) (DADAD), a dynorphin1-13 (DYN) derivative extracted from porcine pituitary, exhibits high potency at peripheral opioid receptors GPI and MVD. Despite rapid in vivo degradation of DYN, this compound shows increased resistance to enzymatic cleavage, enhancing its stability against peptide-degrading enzymes [1].

GIP (1-30) amide, porcine acetate is an agonist of fully glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP (1-30) amide, porcine acetate can weakly inhibit gastric acid secretion and strongly stimulate insulin.

Galanin (1-16), mouse, porcine, rat is a hippocampal galanin receptor agonist(Kd = 3 nM) with high biological activity on locus coeruleus neurons.

Apelin-13 triTFA is the endogenous ligand of the APJ receptor, activating this G protein-coupled receptor with an EC50 value of 0.37 nM.

[(pF)Phe4]Nociceptin(1-13)NH2 acetate is a selective agonist of NOP receptor with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 acetate displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold).

Dynorphin B (1-13) acetate acts as an agonist on opioid κ-receptor.

GnRH Associated Peptide (GAP) (1-13), human Acetate was found to be a potent inhibitor of prolactin secretion and to stimulate the release of gonadotropins. Active immunization with peptides corresponding to GAP sequences led to greatly increased prolacti

Acetyl Angiotensinogen (1-14), porcine Acetate is a peptide with the sequence AC-ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS-LEU-LEU-VAL-TYR-SER-OH. The protein encoded by the Angiotensinogen gene is known as pre-angiotensinogen or angiotensinogen precursor.

Dynorphin A (1-10) acetate is an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC50 of 42.0 μM.

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

Beta-Lipotropin (1-10), porcine Acetate (Beta-Lipotropin ) (beta-LPH) was found to contain within its C-terminal sequence the primary structure of these peptides.

This GIP fragment has potent insulinotropic activity in the isolated, perfused rat pancreas but greatly reduced somatostatinotropic activity in the isolated perfused rat stomach. The site responsible for insulinotropic activity apparently lies between residues 19 and 30 of GIP.

Selective and competitive nociceptin receptor antagonist, devoid of any agonist activity. Binds selectively to recombinant nociceptin receptors (pKi = 8.4), and competitively antagonizes the actions of nociceptin in vitro and in vivo.

Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide.

(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified version of glucagon that exhibits the same maximum glucose-synthesizing activity in rat hepatocytes as its native counterpart. However, its reduced potency indicates the importance of methionine in glucagon's attachment to hepatic receptors [1].

[DPro10] Dynorphin A (1-11), porcine, an N-Alkylated derivative, serves as a potent κ-opioid receptor agonist with a Ki value of 0.13 nM, exhibiting analgesic properties [1] [2].

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) that exerts endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide holds promise for cardiovascular diseases research.

Dynorphin (2-17) (porcine), a Prodynorphin-derived peptide, can alleviate somatic symptoms of Morphine dependence during withdrawal [1].

Dynorphin A (1-13) amide, an endogenous opioid peptide, counteracts the analgesic effects of morphine [1].

(Asp28)-Glucagon (1-29) (human, rat, porcine) is an analog of glucagon with an aspartic acid (Asp) substitution at position 28, notably enhancing its aqueous solubility at physiological pH levels while retaining glucagon's innate biological activity [1].

Apelin-13 is an endogenous ligand of APJ receptor, and the EC 50 value of activated G protein coupled receptor is 0.37 nM.

[DAla2] Dynorphin A (1-9) (porcine) is a dynorphin utilized in research related to analgesic, addiction, and depression studies.

Nociceptin (1-13), amide is a potent ORL1 (OP4) receptor agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds in the transmembrane domain of the κ-receptor.

Glucagon is a peptide hormone, produced by pancreatic α-cells. Glucagon reduces the activity of HNF-4. Glucagon stimulates gluconeogenesis. Glucagon enhances HNF4α phosphorylation.

ACTH (1-13) is a 13-aa peptide, with cytoprotective effects in the model of ethanol induced gastric lesions in rats.Adrenocorticotropic hormone (ACTH), also known as corticotropin, is produced and secreted by the anterior pituitary gland. ACTH is an impor

Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, interacts with κ-opioid receptor's extracellular loop 2 and inhibits NMDA-activated currents with an IC 50 of 42.0 μM.

Biotinyl-Glucagon (1-29), encompassing human, bovine, and porcine versions, is a biotinylated form of glucagon. This peptide hormone, synthesized by the pancreas's α-cells, elevates glucose and fatty acid levels in the bloodstream [1] [2].

Dynorphin (2-17), amide (porcine) is a dynorphin derivative exhibiting analgesic properties. Belonging to the class of opioid peptides synthesized from the precursor protein dynorphinogen, dynorphin plays a pivotal role in regulating pain, addiction, and mood [1].

Dynorphin A (1-10), an endogenous opioid neuropeptide, interacts with the κ-opioid receptor by binding to its extracellular loop 2 and inhibits NMDA-activated current, demonstrating an IC50 value of 42.0 μM.

Potent agonist of the nociceptin (ORL1) receptor, demonstrated both in vitro and in vivo. Selective, competitive antagonism at the nociceptin receptor has also been reported (pA2 = 7.02 and 6.75 in the guinea pig ileum and mouse vas deferens respectively)

Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner.

Dynorphins are a class of opioid peptides that arise from the precursor protein prodynorphin. When prodynorphin is cleaved during processing by proprotein convertase 2 (PC2), multiple active peptides are released: dynorphin A, dynorphin B, and α/β-neo-end

Galanin (1-16), mouse, porcine, rat is an agonist of the hippocampal galanin receptor, with a Kd of 3 nM. Galanin (1-16), mouse, porcine, rat shows high biological activity on locus coeruleus neurons.

Dynorphin (1-8) is an opioid octapeptide from the porcine hypothalamus. It comprises the N-terminal eight residues of dynorphin.

Highly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotrop

Dynorphin B (1-13) acts as an agonist on opioid κ-receptor.

Atrial natriuretic factor (1-28) from both human and porcine sources is a powerful suppressor of pro-opiomelanocortin (POMC) mRNA, while it only has a modest inhibition effect on βEP-LI release.

[DPro10] Dynorphin A (1-11), porcine hydrochloride, is an N-alkylated derivative and a potent κ-opioid receptor agonist, exhibiting a K i value of 0.13 nM. This compound possesses analgesic properties [1] [2].

Gastric inhibitory peptide (GIP) (1-42), an endogenous incretin hormone comprising 42 amino acids, promotes insulin secretion. Expressed in the intestinal neuroendocrine K cells and submandibular gland, it enters circulation after meals. GIP (1-42) blocks histamine, pentagastrin, and insulin-induced gastric acid and pepsin secretion, enhances glucose-stimulated insulin release, and accelerates gastric emptying in rats.

This peptide is a fragment of the alpha-chain of insulin amino acids 1 to 13. The insulin a-chain epitope recognized by human T cells is posttranslationally modified.

Galanin (1-13)-Neuropeptide Y (25-36) amide exhibits high-affinity binding to galanin receptors, similar to that of galanin itself [1].

[Nphe1]Nociceptin(1-13)NH2 is a novel endogenous ligand for the nociceptin/orphanin FQ (NC) receptor, acting as a selective and competitive antagonist without any agonist effects. It binds specifically to recombinant nociceptin receptors with high affinity (pKi=8.4) and effectively blocks nociceptin's ability to inhibit cyclic AMP accumulation in CHO cells (pA2=6.0), showcasing potential as an analgesic agent.

Dynorphin B (1-13) TFA acts as an agonist on opioid κ-receptor .

E-2078, known chemically as (N-Me-Tyr1,N-Me-Arg7,D-Leu-NHEt8)-Dynorphin A (1-8), is a stable analog of Dynorphin A (1–8) and functions as a kappa opioid receptor (KOR) agonist [1].

GIP (1-30) amide, porcine TFA is a high-affinity full agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, having a similar potency as the native GIP(1-42) [1]. Furthermore, GIP (1-30) amide, porcine displays weak inhibitory effects on gastric acid secretion while exhibiting potent insulin-stimulating properties.